← Russell 3000 cross-section

GYRE GYRE THERAPEUTICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$710m
Revenue TTM
$119m
Net income TTM
$-20m
Free cash flow
$-16m
Composite score
47.6
Sector rank
#2218

Valuation

P / E
EV / EBITDA
EV / sales
5.5
FCF yield
-2.22%
Earnings yield vs 10-yr
-7.49pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-16.4%
EBITDA margin
-11.1%
ROE
-18.1%
ROIC
-33.0%
Revenue growth
16.8%

Insider activity, last 90 days

Net open-market
$-0.43m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the six months ended June 30, 2025, we had net income of $2.7 million and net income attributable to common stockholders of $0.1 million. Components of Results of Operations Revenues Sales of Pharmaceutical Products We generate revenue primarily through sales of ETUARY TM , Contiva TM , Etorel TM and certain generic drugs in the PRC. Distributors are our direct customers, and sales to distributors accounted for 100% of the revenue. …GYRE THERAPEUTICS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →